India: Natco to launch Hepatitis C drug in India soon

Natco Pharma plans to launch the generic version of Sovaldi, the blockbuster drug used to treat chronic Hepatitis C in India soon. Sovaldi is made by U.S. pharma major Gilead Sciences, and Natco recently entered into a non-exclusive licensing agreement with Gilead to make and sell generic versions of Sovaldi in 91 developing countries.

The company, on Monday, launched the generic version of Sovaldi in Nepal under the brand Hepcinat. The product is priced at Rs.19,900 (US $316.68) per bottle of 28 tablets in Nepal, and covers the treatment duration of three months for a patient.

“We will be launching the drug in the next few weeks in India, and are awaiting approval from the Drugs Controller General of India (DCGI),” M. Adinarayana, Vice-President, Legal & Corporate Affairs, Natco Pharma, told this correspondent.

Read more...

Labels: , ,